AIMM Therapeutics’ Pre-fusion RSV Antibodies Facilitate Improved Approach ... PharmiWeb.com (press release) AIMM Therapeutics B.V. a leading developer of a new generation of therapeutic antibodies announced today that researchers have used the Company’s unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved ... |
